BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group

K Alsop; S Fereday; C Meldrum; A DeFazio; C Emmanuel; J George; A Dobrovic; MJ Birrer; PM Webb; C Stewart; M Friedlander; S Fox; D Bowtell; G Mitchell

Journal article

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group

K Alsop, S Fereday, C Meldrum, A DeFazio, C Emmanuel, J George, A Dobrovic, MJ Birrer, PM Webb, C Stewart, M Friedlander, S Fox, D Bowtell, G Mitchell

Journal of Clinical Oncology | Published : 2012

DOI: 10.1200/JCO.2011.39.8545

Abstract

Purpose: The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line mutation on response requires further investigation to understand its impact on treatment planning and clinical trial design. Patients and Methods: Women with nonmucinous ovarian carcinoma (n = 1,001) enrolled onto a population-based, case-control study were screened for point mutations and large deletions in both genes. Survival outcomes and responses to multiple lines of chemotherapy were assessed.Results: Germ-line mutations were found in 14.1% of patients overall, including 16.6% of serous cancer patients (high-grade serous, 22.6%); 4..

View full abstract

University of Melbourne Researchers

Related Projects (2)

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Grants

Awarded by Ovarian Cancer Research Program of the US Department of Defense

Awarded by Cancer Australia/National Breast Cancer Foundation

Awarded by U.S. Army Medical Research and Materiel Command

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

Supported by Grants No. W81XWH-08-1-0684 and W81XWH-08-1-0685 of the Ovarian Cancer Research Program of the US Department of Defense, Grants No. 509303, 509366, and 632595 from Cancer Australia/National Breast Cancer Foundation, the Peter MacCallum Cancer Centre Foundation, and the Cancer Council Victoria (postgraduate scholarship to K.A.). The Australia Ovarian Cancer Study was supported by Grant No. DAMD17-01-1-0729 of the U.S. Army Medical Research and Materiel Command; Grants No. 400281 and 400413 of the National Health and Medical Research Council of Australia; Cancer Council Victoria, Cancer Council Queensland, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, and Cancer Council Tasmania.